Feasibility of re‐biopsy and EGFR mutation analysis in patients with non‐small cell lung cancer

BACKGROUND: In cases of EGFR‐tyrosine kinase inhibitor (TKI) failure, re‐biopsy may be useful to understand resistance mechanisms and guide further treatment decisions. However, performing re‐biopsy is challenging because of several hurdles. We assessed the feasibility of re‐biopsy in advanced non‐s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae‐Ok, Oh, In‐Jae, Kho, Bo Gun, Park, Ha Young, Chang, Jin Sun, Park, Cheol‐Kyu, Shin, Hong‐Joon, Lim, Jung‐Hwan, Kwon, Yong‐Soo, Kim, Yu‐Il, Lim, Sung‐Chul, Kim, Young‐Chul, Choi, Yoo‐Duk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026616/
https://www.ncbi.nlm.nih.gov/pubmed/29761660
http://dx.doi.org/10.1111/1759-7714.12762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026616/
https://www.ncbi.nlm.nih.gov/pubmed/29761660
http://dx.doi.org/10.1111/1759-7714.12762

Ejemplares similares